Fri Sep 20 08:46:59 UTC 2024: ## TransMedics CEO Sells $1.3 Million Worth of Stock

**Boston, MA** – TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock on Monday, September 16th, for a total of $1,323,247.50. The transaction was disclosed in a filing with the Securities & Exchange Commission.

Following the sale, Hassanein now owns 61,643 shares of TransMedics stock, valued at $9,457,269.06. This comes amidst a period of positive financial performance for the company. In the second quarter, TransMedics exceeded analysts’ expectations, reporting $0.35 earnings per share and $114.30 million in revenue.

TransMedics Group is a commercial-stage medical technology company specializing in organ transplant therapy. The company’s flagship product, the Organ Care System (OCS), is designed to optimize donor organs outside of the body, potentially improving transplant outcomes.

While the CEO’s stock sale has raised some eyebrows, analysts remain optimistic about TransMedics’ future prospects. They forecast earnings per share of 1.23 for the current year.

The company’s stock opened at $165.98 on Friday, with a market capitalization of $5.47 billion. The 50-day moving average is $155.19 and the 200-day moving average is $128.44.

**Note:** This news article was rewritten based on the provided text, summarizing the key points and presenting them in a clear and concise manner.

Read More